Adding a specific medication to hormone therapy extends life for some breast cancer patients
In short: A study of 334 postmenopausal women with advanced breast cancer found that combining the drug ribociclib with letrozole significantly extended overall survival compared to using letrozole alone. While previous data showed the combination slowed disease progression, this trial confirmed that patients receiving the dual treatment lived longer.
The researchers conducted a randomized trial where patients were split into two groups. The results showed a median survival of 63.9 months for those on the combination therapy versus 51.4 months for those on the placebo. However, as a secondary endpoint, these results are part of a broader hierarchical testing strategy.
Why it matters: This research provides evidence that adding ribociclib to standard hormone therapy can meaningfully extend life for certain advanced breast cancer patients.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Hortobagyi et al. (2022). Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. The New England journal of medicine.
To cite this card, link to https://intellectplus.co.uk/app/health-research-adding-a-specific-medication-to-hormone-therapy-extends-life.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Clinical trials · More in Health · Latest · A–Z · All topics
